USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ELECTRONIC BIOSCIENCES, INC.
Address:
5754 PACIFIC CENTER BLVD, #204
SAN DIEGO, CA 92121-4207
Phone:
N/A
URL:
N/A
EIN:
127448492
DUNS:
129852864
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $741,839.00 4
SBIR Phase II $1,800,317.00 2

Award List:

Nanopore Based Methods for Enantiomer Differentiation

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$168,098.00
Agency:
HHS
Principal Investigator:
Eric Ervin
Abstract:
DESCRIPTION (provided by applicant): The overall aim of this Phase I program is to develop a new, robust nanopore platform for the differentiation of pharmacologically relevant enantiomers in clinical samples. Enantiomer screening is an important aspect of drug manufacturing and pharmacokinetic… More

Nanopatch System for Next Generation Ion Channel Recordings

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$800,329.00
Agency:
HHS
Principal Investigator:
Geoffrey Barrall – 858-228-3205
Abstract:
DESCRIPTION (provided by applicant): This Phase II SBIR program aims to further develop Electronic Bio Sciences' (EBS) Nanopatch system for ion channel measurements. The proposed system will allow high sensitivity measurements previously only attainable with the patch clamp method to be… More

Development of an in vitro assay as correlate of passive immune protection against botulinum neurotoxin to minimize use of whole animal testing

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$149,949.00
Agency / Branch:
DOD / CBD
Principal Investigator:
Eric Ervin, Vice President R&D - EBS Utah – (801) 582-0146
Abstract:
This Small Business Innovation Research Phase I project will develop a non-animal based in-vitro assay for determining the efficacy of Botulinum (BoNT) neutralizing therapeutics; the dual nanopore assay (DNPA). New technologies are currently needed in order to facilitate the development and approval… More

Development of an in vitro assay as correlate of passive immune protection against botulinum neurotoxin to minimize use of whole animal testing

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$999,988.00
Agency / Branch:
DOD / CBD
Principal Investigator:
Eric Ervin, Vice President of R&D – (801) 582-0146
Abstract:
This Small Business Innovation Research project will develop a non-animal based in vitro assay for determining the efficacy of Botulinum (BoNT) neutralizing therapeutics. New technologies are currently needed in order to facilitate the development and approval of BoNT vaccines and therapies and… More

Encapsulated Lipid Bilayer Based Assay for Assessing Botulinum Neurotoxin Potency

Award Year / Program / Phase:
2012 / SBIR / Phase I
Award Amount:
$184,864.00
Agency:
HHS
Principal Investigator:
Eric Ervin – 858-412-1705
Abstract:
DESCRIPTION (provided by applicant): Unknown or poorly understood differences in the potency of therapeutics containing the botulinum neurotoxin Type A (BoNT/A) could result in over or under dosing of patients. The potency of BoNT/A therapeutics is currently assessed using a mouse intraperitoneal… More

Accurate, long read length, whole human genome sequencing under 100

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$238,928.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The aim of this project is to investigate a simple method for slowing down the rate of electrophoretic translocation of DNA through a nanopore. Unique modulations of current across nanopores produced by individual basesduring such translocation forms the basis of… More